Abide Therapeutics' Corporate Minority Round

Abide Therapeutics raised a round of funding on February 28, 2014. Investors include Celgene.

Abide Therapeutics is focused on developing innovative medicines that target serine hydrolases, one of the largest enzyme classes in nature with validated but mostly untapped therapeutic potential. Se…

Articles about Abide Therapeutics' Corporate Minority Round: